Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. (Q40383031)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112911 AND SRC:MED&resulttype=core&format=json

5 January 2020

title

Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112911 AND SRC:MED&resulttype=core&format=json

5 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112911 AND SRC:MED&resulttype=core&format=json

5 January 2020

Dave S. Hoon

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112911 AND SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Yasufumi Kaneda

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112911 AND SRC:MED&resulttype=core&format=json

5 January 2020

Sharon Huang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112911 AND SRC:MED&resulttype=core&format=json

5 January 2020

Suzanne H Hiramatsu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112911 AND SRC:MED&resulttype=core&format=json

5 January 2020

language of work or name

1 reference

22 August 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112911 AND SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112911 AND SRC:MED&resulttype=core&format=json

5 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112911 AND SRC:MED&resulttype=core&format=json

5 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112911 AND SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

194-202

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16112911 AND SRC:MED&resulttype=core&format=json

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Dendritic cells injected via different routes induce immunity in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Immunomodulation of cancer: potential use of selectively replicating agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

The biology of chemokines and their receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

The role of chemokine receptors in primary, effector, and memory immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Pigment production in murine melanoma cells is regulated by tyrosinase, tyrosinase-related protein 1 (TRP1), DOPAchrome tautomerase (TRP2), and a melanogenic inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Distinct dendritic cell subsets differentially regulate the class of immune response in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Codelivery of CCR7 ligands as molecular adjuvants enhances the protective immune response against herpes simplex virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

DNA-based immunization by in vivo transfection of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

DNA vaccination: transfection and activation of dendritic cells as key events for immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Induction of antibody response to human tumor antigens by gene therapy using a fusigenic viral liposome vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Hemagglutinating virus of Japan protein is efficient for induction of CD4 T-cell response by a hepatitis B core particle-based HIV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Expansion of melanoma-specific cytolytic CD8 T cell precursors in patients with metastatic melanoma vaccinated with CD34 progenitor-derived dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018

A tumor-homing peptide with a targeting specificity related to lymphatic vessels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YMTHE.2005.05.018